Q3 EPS Forecast for PROCEPT BioRobotics Decreased by Analyst

Key Points

• Leerink Partnrs has lowered its Q3 2025 EPS estimate for PROCEPT BioRobotics to ($0.45), down from a previous estimate of ($0.39).
• The consensus forecast for PROCEPT BioRobotics' full-year earnings is ($1.75) per share, with projections indicating losses will continue into the next several years.
• PROCEPT BioRobotics has reported a strong 48.3% increase in quarterly revenue compared to the same period last year, totaling $79.18 million.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) - Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for shares of PROCEPT BioRobotics in a research note issued on Thursday, August 7th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of ($0.45) per share for the quarter, down from their previous estimate of ($0.39). The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics' FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($1.14) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.33) EPS.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06. PROCEPT BioRobotics had a negative return on equity of 23.73% and a negative net margin of 30.60%. The company had revenue of $79.18 million during the quarter, compared to analyst estimates of $75.67 million. During the same period in the previous year, the company earned ($0.50) EPS. The company's revenue for the quarter was up 48.3% compared to the same quarter last year.

A number of other equities analysts also recently weighed in on PRCT. Wall Street Zen raised PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Piper Sandler dropped their price objective on PROCEPT BioRobotics from $80.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Stephens began coverage on PROCEPT BioRobotics in a research note on Wednesday, July 9th. They issued an "overweight" rating and a $70.00 price target on the stock. Morgan Stanley lowered their price objective on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 15th. Finally, Oppenheimer started coverage on PROCEPT BioRobotics in a report on Monday, July 7th. They set a "market perform" rating on the stock. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $74.88.

PROCEPT BioRobotics Stock Down 3.2%

Shares of PRCT traded down $1.27 on Monday, hitting $39.11. The company's stock had a trading volume of 538,369 shares, compared to its average volume of 1,021,620. PROCEPT BioRobotics has a fifty-two week low of $37.12 and a fifty-two week high of $103.81. The company has a quick ratio of 7.86, a current ratio of 9.21 and a debt-to-equity ratio of 0.13. The firm's fifty day moving average price is $55.73 and its 200-day moving average price is $58.26. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of -25.23 and a beta of 1.05.

Hedge Funds Weigh In On PROCEPT BioRobotics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of PROCEPT BioRobotics by 9.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,779 shares of the company's stock worth $527,000 after acquiring an additional 723 shares during the period. GAMMA Investing LLC lifted its stake in PROCEPT BioRobotics by 7,021.1% in the first quarter. GAMMA Investing LLC now owns 6,409 shares of the company's stock valued at $373,000 after buying an additional 6,319 shares during the period. Bessemer Group Inc. lifted its stake in PROCEPT BioRobotics by 50.7% in the first quarter. Bessemer Group Inc. now owns 10,900 shares of the company's stock valued at $635,000 after buying an additional 3,665 shares during the period. Mariner LLC lifted its stake in PROCEPT BioRobotics by 40.6% in the fourth quarter. Mariner LLC now owns 8,406 shares of the company's stock valued at $677,000 after buying an additional 2,429 shares during the period. Finally, Rhumbline Advisers lifted its stake in PROCEPT BioRobotics by 5.0% in the first quarter. Rhumbline Advisers now owns 64,373 shares of the company's stock valued at $3,750,000 after buying an additional 3,077 shares during the period. 89.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 25,000 shares of PROCEPT BioRobotics stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $61.49, for a total value of $1,537,250.00. Following the transaction, the director directly owned 14,363 shares of the company's stock, valued at $883,180.87. The trade was a 63.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 100,000 shares of company stock worth $6,271,250 over the last quarter. Company insiders own 6.60% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).